How cuts to marginal income tax could boost the UK’s stagnant economic growth 
Japan Posts 7.7% Growth in Machinery Orders 
Whirlpool’s Stale Demand Led to 1,000 Job Cuts in the US 
The yen plunges to 34-year low despite interest rate hike 
China’s new world order: looking for clues from Xi’s recent meetings with foreign leaders 
Family farms are fast disappearing: our research shows how young generations can take them up successfully 
The idea that US interest rates will stay higher for longer is probably wrong 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
Toyota Teams with Tencent, Nissan Joins Forces with Baidu in China AI Drive 
If plastic manufacturing goes up 10%, plastic pollution goes up 10% – and we’re set for a huge surge in production 
Chipotle Scraps Farmesa Fresh Eatery spinoff, Ghost Kitchen Cease Operations 
Hermes Surpasses Expectations with a 17% Surge in First-Quarter Sales 
Impact of Iran-Israel conflict on Stocks, Gold and Bitcoin 
EU enlargement: What does the future hold? 
New Study Reveals Coke, Pepsi, and Nestle as Top Plastic Polluters 
Tesla Nears FSD Licensing Deal with Major Automaker, Hits 1.3 Billion Milestone 
Samsung Group is currently negotiating to acquire Biogen Inc., the American biotech company headquartered in Cambridge, Massachusetts. If the talks turn out to be successful, it will be the South Korean manufacturing conglomerate's biggest transaction ever.
Samsung Group is really interested in the mega-deal proposal from Biogen Inc., and this is set to become its largest acquisition. In 2016, the company set a record for its largest transaction ever after buying Harman, an American electronics systems maker for vehicles, for $8 billion. Now, its possible acquisition of the biotech firm will top this amount by more than five times over.
According to The Korea Economic Daily, Biogen Inc. spoke to Samsung to offer some of its shares that could be worth over ₩50 trillion or about $42 billion, including the control premium. The biotech firm's market cap at the moment is moderately less than $35 billion.
An investment banking source revealed on Wednesday, Dec. 29, that Samsung Group may buy the US-based drugmaker that specializes in neurological diseases, including dementia and Alzheimer's. "Samsung is at the negotiating table with the sell-side to acquire Biogen," a senior official at a global investment bank told KED.
In case the stake acquisition turns out to be successful, Samsung will become one of the top-ranking global biotechnology companies. It will also be able to expand its pharmaceutical business and do more aside from biosimilar treatment drugs and manufacturing deals. As for Biogen, it is also expected to steadily make high operating profits once the deal is sealed.
"Samsung is nurturing bio business as a new growth engine," another insider stated. "Acquiring Biogen will create an opportunity to take a quantum leap."
If the acquisition talks failed, it was reported that Samsung would attempt to buy back the remaining stake owned by Biogen in Samsung Bioepis, their biosimilar joint venture. Meanwhile, the response to the acquisition news was good so far as Biogen's stock went up after the report was published.
Market Watch reported that Biogen's shares increased 8.9 percent in the afternoon trading on Wednesday, just after it was reported that Samsung Group is on the negotiation table with the US-based drugmaker to purchase stakes in the company that is valued at around $42 billion.
